Milmiga (Liraglutide)

Liraglutide mimics the action of natural GLP‑1, binding to its receptor on pancreatic beta cells. This enhances glucose‑dependent insulin secretion, suppresses excess glucagon, slows gastric emptying, and increases satiety, leading to improved glycaemic control and reduced caloric intake.

The dose of Milmiga is individualized by the prescribing healthcare professional. Initiation typically starts with a low dose that is gradually increased based on therapeutic response and tolerability, following the prescriber’s clinical judgment and local guidelines.

Liraglutide is generally not recommended during pregnancy or lactation unless the potential benefit justifies the potential risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To order Milmiga, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Milmiga (liraglutide) shares the class‑wide mechanisms of GLP‑1 agonists but differs in dosing frequency and specific trial data. Compared with weekly agents, liraglutide requires daily subcutaneous injections, which may allow finer titration. Efficacy in glycaemic control and weight loss is comparable, while safety profiles are similar across the class.

Milmiga must be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the product in its original carton, protect it from light, and avoid freezing or shaking. If a short‑term temperature excursion occurs, the product may be used for up to 30 days at controlled room temperature, as per the manufacturer’s guidance.

Milmiga is given as a subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection should be performed using a sterile, single‑use pen or syringe, following proper aseptic technique. Patients are advised to rotate injection sites to reduce local irritation.

The most serious adverse events linked to liraglutide include acute pancreatitis, severe hypoglycemia (especially when combined with insulin or sulfonylureas), and a potential risk of thyroid C‑cell tumors, which has been observed in animal studies. Prompt medical attention is required if any of these conditions develop.

Milmiga is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or known hypersensitivity to liraglutide or any excipients. Caution is also advised for patients with severe renal impairment, a history of pancreatitis, or those who are pregnant or breastfeeding.